Trial reportEuropean journal of medical research2025
Impact of TauroLock
Trial report in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Clinical Pharmacist-Led Medication Management on Medication Adherence and Quality of Life in Stroke Patients Undergoing Intravenous Thrombolysis.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCentral venous catheters (CVCs) are essential for drug delivery in pediatric oncology patients but are associated with complications such as infection and thrombosis. This study aimed to compare the effects of taurolidine-citrate and unfractionated heparin lock solutions on catheter function, infection and thrombosis rates, and inflammatory markers in children with malignancies.
methodsIn this randomized, controlled trial, 76 pediatric oncology patients were allocated to receive either TauroLock
resultsAt 6 months, hs-CRP levels were significantly lower in the taurolidine-citrate group (2.1 ± 0.2 vs. 5.5 ± 2.2, p = 0.001), as was total WBC count (3792.1 ± 325.3 vs. 4994.5 ± 462.1, p = 0.028). IL-6 levels showed no statistically significant difference (9.2 ± 1.9 vs. 14.0 ± 3.1, p = 0.067). The incidence of catheter-related infections (HR 3.55, 95% CI 0.68-18.4, p = 0.460) and thrombosis (HR 4.13, 95% CI 0.43-39.91, p = 0.221) did not differ significantly between groups.
conclusionTaurolidine-citrate exhibited a modest anti-inflammatory effect, reflected by reduced hs-CRP and WBC levels, without significant improvement in catheter-related complications or IL-6. The lack of major clinical benefit may relate to the heterogeneous and immunocompromised nature of pediatric oncology patients. Larger, adequately powered studies are warranted to clarify the long-term efficacy and safety of taurolidine-citrate in this population. Clinical Trials as IRCT20201107049296N4.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.